A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
Myeloproliferative Neoplasms
DRUG: INCA033989|DRUG: Ruxolitinib
Number of participants with Dose Limiting Toxicities (DLTs), Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol., Up to 28 days|Number of participants with Treatment-emergent Adverse Events (TEAEs), Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with ruxolitinib, Up to 3 years and 60 days|Number of participants with TEAEs leading to dose modification or discontinuation, Number of participants with TEAEs leading to dose modification or discontinuation., Up to 3 years and 60 days
Participants with MF: Response using the revised IWG-MRT and ELN response criteria for MF, Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria., Up to 3 years and 60 days|Participants With MF: Percentage of participants achieving spleen volume reduction as defined in the protocol, Defined as percentage of participants with a protocol defined Spleen Volume Reduction., Up to 3 years and 60 days|Participants with MF with symptomatic anemia: Anemia Response, For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol., Up to 3 years and 60 days|Participants With ET: Response Rate, Defined as the proportion of participants with Complete Response or Partial Response when treated with study drug., Up to 3 years and 60 days|Participants With ET: Mean change from baseline of total symptom score (TSS), Mean change of TSS from baseline., Up to 3 years and 60 days|Mean change in disease-related allele burden, Mean change in disease-related allele burden., Up to 3 years and 60 days|Pharmacokinetics Parameter: Cmax of INCA33989, Defined as maximum observed plasma concentration of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: Tmax of INCA033989, Defined as the time to reach the maximum plasma concentration of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: Cmin of INCA33989, Defined as the minimum observed plasma concentration of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: AUC(0-t) of INCA33989, Defined as the area under the concentration-time curve up to the last measurable concentration of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: AUC 0-âˆž of INCA33989, Defined as the area under the concentration-time curve from 0 to infinity of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: CL/F of INCA33989, Defined as the apparent oral dose clearance of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: Vz/F of INCA33989, Defined as the apparent oral dose volume of distribution of INCA33989., Up to 3 years and 60 days|Pharmacokinetics Parameter: t1/2 of INCA33989, Defined as the apparent terminal phase disposition half-life of INCA33989., Up to 3 years and 60 days
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.